Clinical trials located in


Martin city is located in Slovakia. Currently, 14 clinical trials are being conducted in this city.

Martin, nestled in northern Slovakia, is a city steeped in cultural significance. It serves as the heart of the Slovak National Revival, housing the Slovak National Museum and the revered Slovak National Cemetery, where many prominent figures are laid to rest. The city’s landscape is adorned with historical architecture, including the Church of St. Martin, from which it derives its name. Martin is also renowned for its role in education, hosting several institutions that contribute to its vibrant intellectual atmosphere.

  • CT-EU-00117573

    Study of Combination Therapy for Melanoma After Anti-PD-1 Treatment

    This clinical trial is comparing two different treatment approaches for advanced melanoma, which is a type of skin cancer that has spread to other parts of the body. If you have a specific gene mutation called BRAF and have previously received treatment with certain immunotherapy drugs like nivolumab or pembrolizumab, you may be eligible for this study.

    One treatment approach involves receiving three study medicines: pembrolizumab given through an IV every 3 weeks, along with encorafenib and binimetinib taken by mouth daily at home. The other approach involves receiving two study medicines: ipilimumab and nivolumab given through an IV every 3 weeks for the first 4 doses, followed by nivolumab alone every 4 weeks. Both treatment approaches will be given for around 2 years, but there is no time limit for the encorafenib and binimetinib treatment.

    The study team will closely monitor your condition during regular visits to the clinic to see how you are responding to the treatment. The main goal is to determine which treatment approach is more effective in shrinking or eliminating the melanoma tumors. Around 150 participants will be enrolled in this study and randomly assigned to one of the two treatment groups.

    CzechiaGermanyItalyPolandSlovakiaSpainUnited Kingdom
  • Testing Milvexian’s effectiveness in preventing repeat strokes

    This research trial, called LIBREXIA-STROKE, will test a medication called Milvexian on those who have recently had a stroke or a high-risk ‘mini-stroke’. In its 3rd testing phase, the study will involve a system where the patients won’t know whether they are receiving the actual drug or a substitute with no effect, referred to as a ‘placebo’, to maintain fairness. Milvexian is a medication that can potentially reduce the risk of having another stroke, and this trial aims to observe how effective it is in doing so. The trial will look at when the first stroke happens after starting the trial, if other major heart or limb diseases occur, or if strokes occur in the first 90 days.

    AustriaBelgiumBulgariaCzechiaDenmarkFinlandFranceGermanyHungaryItalyNetherlandsPolandPortugalRomaniaSlovakiaSpainSwedenUnited Kingdom
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Long-term study on ofatumumab effects in relapsing multiple sclerosis atients

    This study is being conducted to assess the safety of long-term usage of a drug called ofatumumab in patients with relapsing multiple sclerosis, a condition that can disrupt the nervous system. As part of the study, an investigation is being carried out to determine the ease of administration and the efficacy of the drug. Individuals who have previously participated in other studies involving ofatumumab for multiple sclerosis are eligible to enroll in this study. A sub-study is also being conducted to examine the impact of ofatumumab on the body’s response to specific vaccines and an antigen known as KLH. Antigens are substances capable of triggering the production of antibodies in the body. Progress will be assessed based on the annual frequency of disease relapses and changes in disability, using the EDSS scale. EDSS evaluates factors such as vision, brain function, and walking ability.

    BulgariaCzechiaFranceGreeceHungaryPolandPortugalSlovakiaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Impact of apalutamide on hormone-sensitive prostate cancer

    This is a study on prostate cancer, particularly patients suffering from a high-risk, hormone-sensitive form. The researchers want to check how adding a drug called apalutamide to the regular treatment can affect the cancer. The standard treatment includes radiotherapy and a drug that blocks the hormone responsible for cancer growth, known as LHRH. This study will check if adding apalutamide can delay the cancer from spreading or help patients live longer. The researchers will track disease progress using a special imaging test called PSMA-PET. They will also monitor changes in PSA, a protein made by the prostate that rises when cancer is present. Other important measures include how long it takes for the cancer to spread and the general rate of survival.

  • Testing Marstacimab for children with Hemophilia A or B

    This trial is all about a drug called Marstacimab. Its effectiveness will be examined in children diagnosed with Hemophilia A or B. All participants in this study will receive Marstacimab to use prophylactically. This drug will be given once a week as a subcutaneous (under the skin) shot. The first dose of marstacimab will be given at the study site by the study site staff. During the 12-month treatment period, weekly doses of marstacimab can be given at home, or if preferred, the doses may be given by the study site staff. Marstacimab can help improve the condition of these children.

    AustriaDenmarkFranceGermanyItalySlovakiaSpainUnited Kingdom
  • Long-term safety study of sebetralstat in treating hereditary angioedema

    This trial is about a medicine sebetralstat also known as KVD900, which is being tested as a treatment to quickly stop swelling attacks in teenagers and adults who have a condition called hereditary angioedema (HAE). HAE is a rare, inherited disorder that causes episodes of swelling in different parts of the body. The study aims to find out how safe this medicine is if used for a long time. People who are 12 years and older and who have HAE type I or II can participate in this trial. One of the things the researchers will look at is how fast symptoms start to get better after taking this new medication.

    AustriaBulgariaFranceGermanyGreeceHungaryItalyNetherlandsPolandPortugalRomaniaSlovakiaSpainUnited Kingdom
  • Testing the effect of sebetralstat treatment in hereditary angioedema

    This study focuses on adolescents with hereditary angioedema (HAE) type I or II. It aims to evaluate the effectiveness of Sebetralstat (KVD900), a drug intended to treat this disease. Teenagers taking part in this study will be given KVD900 to see how it affects their symptoms. The study is needed to understand how this drug may help treat HAE in younger patients, offering a potential new treatment option. Throughout the study, participants’ health and response to the drug will be closely monitored, with their safety and well-being being a priority. This research could significantly improve the treatment of hereditary angioedema in adolescents.

    AustriaBulgariaFranceGermanyGreeceNetherlandsRomaniaSlovakiaSpainUnited Kingdom
  • Evaluating the impact of upadacitinib on Hidradenitis Suppurativa

    The aim of this study is to evaluate the effects of a drug called upadacitinib on people suffering from a skin condition called Hidradenitis Suppurativa (HS). HS causes painful sores, mainly in areas such as the armpits, groin, and anal and genital areas. The drug has already been approved to treat other conditions, such as ulcerative colitis and rheumatoid arthritis, but now doctors want to see if it can help HS patients who don’t respond to current treatments. The study was divided into three parts. First, participants will be randomly assigned to two different groups, one group will take upadacitinib and the other will take a placebo (a substance with no active effect). Neither participants nor doctors will know what treatment a person is receiving. The study lasts a year and a half, and patients take pills every day. Depending on the results obtained, they may proceed to further stages of the study. Participants’ health will be closely monitored through regular check-ups, surveys, and monitoring for any side effects.

  • Exploring tezepelumab’s effect in treating eosinophilic esophagitis

    This study is about testing tezepelumab, a new medicine, for treating eosinophilic esophagitis (EoE), a throat condition, in teenagers and adults. It compares tezepelumab with a placebo (a treatment with no active drug) over 52 weeks, with an optional extra 24 weeks of treatment, followed by a 12-week safety follow-up. Doctors will check if tezepelumab helps reduce throat inflammation and makes swallowing easier for patients.

    AustriaBelgiumCzechiaDenmarkFinlandGermanyGreeceItalyNetherlandsNorwaySlovakiaSpainSwedenUnited Kingdom
  • Psoriatic arthritis study with tildrakizumab

    The trial is enrolling participants with psoriatic arthritis to continue treatment with tildrakizumab, an injectable drug. This is an open-label Phase 3 study that focuses on the drug’s long-term effects and aims to track any side effects and its effectiveness in helping to treat arthritis symptoms. The aim is to better understand the effectiveness of tildrakizumab over the long term and ensure it can be used safely on an ongoing basis.

  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    BelgiumDenmarkFinlandFranceGermanyNetherlandsNorwayPortugalSwedenUnited Kingdom
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.


See more clinical trials in other cities in Slovakia: